



PHARMACEUTICAL 2018

uniQure uniQure N.V.







PHARMACEUTICAL 2018

uniQure N.V. Rank 147 of 349



The relative strengths and weaknesses of uniQure N.V. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of uniQure N.V. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 40% points. The greatest weakness of uniQure N.V. is the variable Research and Development, reducing the Economic Capital Ratio by 57% points.

The company's Economic Capital Ratio, given in the ranking table, is -132%, being 145% points above the market average of -278%.

Input Variable	Value in 1000 USD
Assets, Current	162,783
Cost of Goods Sold	0
Intangible Assets	10,100
Liabilities, Current	19,230
Liabilities, Non-Current	101,055
Other Assets	2,480
Other Compr. Net Income	2,757
Other Expenses	5,106
Other Liabilities	0
Other Net Income	9,546
Property and Equipment	34,281
Research and Development	72,172
Revenues	13,107
Selling, General and Administrative Expense	24,635

Output Variable	Value in 1000 USD
Assets	209,644
Liabilities	120,285
Expenses	101,913
Stockholders Equity	89,359
Net Income	-79,260
Comprehensive Net Income	-77,882
Economic Capital Ratio	-132%